{"id":"NCT00765817","sponsor":"AstraZeneca","briefTitle":"Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus","officialTitle":"A Randomized Trial Comparing Exenatide With Placebo in Subjects With Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10","primaryCompletion":"2010-01","completion":"2010-01","firstPosted":"2008-10-03","resultsPosted":"2011-01-26","lastUpdate":"2016-10-24"},"enrollment":261,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"exenatide","otherNames":[]}],"arms":[{"label":"1","type":"PLACEBO_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"This study will compare the efficacy and safety of exenatide versus placebo in adults whose diabetes is not fully controlled by insulin glargine with or without metformin and/or pioglitazone.","primaryOutcome":{"measure":"Change in Glycosylated Hemoglobin (HbA1c)","timeFrame":"baseline and 30 weeks","effectByArm":[{"arm":"Exenatide Arm","deltaMin":-1.71,"sd":0.09},{"arm":"Placebo Arm","deltaMin":-1,"sd":0.09}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":18},"locations":{"siteCount":59,"countries":["United States","Greece","Israel","Mexico","Puerto Rico","United Kingdom"]},"refs":{"pmids":["24621255","23043166","22913891","22432107","21138825"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":137},"commonTop":["Nausea","Diarrhea","Vomiting","Headache","Upper Respiratory Tract Infection"]}}